New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
09:51 EDTNYMXNymox reports results on side effect profile of NX-1207 treatment
Nymox Pharmaceutical Corporation reports new positive data confirming the advantageous side effect profile of the company's lead compound NX-1207. Results from the Brief Male Sexual Function Questionnaire in the company's recently completed NX03-0040 trial of NX-1207 2.5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no significant effect on reported sexual function score post-treatment. Currently approved drugs for prostate enlargement can produce significant sexual side effects such as impotence, decreased libido, ejaculation disorders, and male breast enlargement. NX-1207 has been shown not to have these sexual drawbacks in results to date. As well, certain of the approved BPH drugs, including the combination drug therapies, are also associated with an increased risk of high-grade prostate cancer. By contrast, the area of the prostate targeted with NX-1207 treatment showed less prostate cancer progression with less radiation and surgery due to cancer progression as compared to controls in the recent NX03-0040 trial. Nymox recently announced the completion of its second pivotal Phase 3 trial of NX-1207 for BPH, NX02-0018, and top-line results for its Phase 2 trial of NX-1207 for localized low risk prostate cancer, NX03-0040.
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
10:03 EDTNYMXNymox says Phase 2 NX03-0040 study successfully met pre-determined endpoints
Nymox Pharmaceutical Corporation announced results from the completion of the company's U.S. 40 month localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate. The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.The clinical trial commenced in February 2012 at 28 U.S. investigational clinical trial sites and enrolled 147 patients with low grade localized prostate cancer. The study lasted 40 months overall from the first patient randomized to the last patient 18 month endpoints. "These results demonstrate that a single targeted office injection of fexapotide has led to statistically significant improvement in outcomes with much less surgery or radiotherapy required after 18 months. This means a reduction in patient discomfort, and a reduction in permanent side effects and life changes when the more invasive treatments are required," said Paul Averback, CEO of Nymox.
February 4, 2016
11:19 EDTNYMXNymox announces private placement equity investment of $2.1M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use